



ELSEVIER

Systems analysis of West Nile virus infection

Mehul S Suthar^{1,3} and Bali Pulendran^{2,3}

Emerging and re-emerging mosquito-borne viruses continue to pose a significant threat to human health throughout the world. Over the past decade, West Nile virus (WNV), Dengue virus (DENV), and Chikungunya virus (CHIKV), have caused annual epidemics of virus-induced encephalitis, hemorrhagic fever/shock syndromes, and arthritis, respectively. Currently, no specific antiviral therapies or vaccines exist for use in humans to combat or prevent these viral infections. Thus, there is a pressing need to define the virus–host interactions that govern immunity and infection outcome. Recent technological breakthroughs in ‘omics’ resources and high-throughput based assays are beginning to accelerate antiviral drug discovery and improve on current strategies for vaccine design. In this review, we highlight studies with WNV and discuss how traditional and systems biological approaches are being used to rapidly identify novel host targets for therapeutic intervention and develop a deeper conceptual understanding of the host response to virus infection.

Addresses

¹ Department of Pediatrics and Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30329, USA

² Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA

³ Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA

Corresponding author: Suthar, Mehul S (msuthar@emory.edu)

Current Opinion in Virology 2014, 6:70–75

This review comes from a themed issue on **Viral pathogenesis**

Edited by **Mark Heise**

<http://dx.doi.org/10.1016/j.coviro.2014.04.010>

1879-6257/© 2014 Elsevier B.V. All rights reserved.

Emerging mosquito-borne viruses

Emerging and re-emerging mosquito-borne viruses continue to pose a significant threat to human health throughout the world. Over the past decade, West Nile virus (WNV), Dengue virus (DENV), and Chikungunya virus (CHIKV), have caused annual epidemics of virus-induced encephalitis, hemorrhagic fever/shock syndromes, and arthritis, respectively. Since its introduction to the United States in 1999, WNV has been estimated to cause more than 3 million infections, resulting in over 780 000 illnesses, 38 000 clinically confirmed cases, and 1500 deaths

between 1999 and 2014 [1,2]. Since the 1960s, DENV has emerged in the Americas, southeast Asia, and the Indian subcontinent and has been estimated to cause 50–100 million infections per year and a total of 2.5 billion people worldwide are at risk of infection. In 2005, a major outbreak of CHIKV occurred on the Reunion Island off the western coast of Africa, resulting in annual epidemics of CHIKV infection in Africa, southeast Asia, India and Australia [3]. Most recently, CHIKV has spread to the Americas, with over 8000 suspected cases within the Caribbean islands [4]. This is the first documented outbreak of autochthonous CHIKV in the Americas. Currently, no specific antiviral therapies or vaccines exist for use in humans to combat or prevent these mosquito-borne infections. Thus, there is a pressing need to define the virus-host interactions that govern immunity and infection outcome. Recent technological advancements in ‘omics’ resources and high-throughput based assays are beginning to accelerate antiviral drug discovery and improve on current strategies for vaccine design. In this review, we highlight studies with WNV and discuss how traditional and systems biological approaches are being used rapidly identify novel host targets for therapeutic intervention and develop a deeper conceptual understanding of the host response to virus infection.

West Nile virus pathogenesis

WNV infection of mice has provided valuable insight into the pathogenesis of virus infection in humans (reviewed in [5]). Three distinct stages of WNV pathogenesis have been defined through studies in mice: initial infection and spread (early phase), peripheral virus amplification (viremic phase), and neuroinvasion (central nervous system (CNS) phase). The early phase is defined by WNV infection and replication at the site of inoculation, in keratinocytes [6], dermal dendritic cells and skin-resident Langerhans cells [7]. The viremic phase is defined by virus spread to the spleen, a primary site for peripheral virus replication, and non-productive infection of other peripheral organs (e.g. liver and kidney). During these first two stages, dendritic cells, macrophages, and possibly neutrophils are believed to be the key target cells of infection [8–10]. While the specific dendritic cell or macrophage subsets that amplify WNV *in vivo* have yet to be identified, genetic deletion of CD8⁺α DCs or antibody-mediated depletion of macrophages lead to dysregulated host control of virus replication, increased mortality, and defects in adaptive immunity [9,11,12,13]. The final stage involves WNV neuroinvasion into the central nervous system, where the virus targets and replicates in neuronal subsets. These distinct stages of pathogenesis are believed to recapitulate what

occurs in humans following WNV transmission by a mosquito bite.

Following virus infection of a target host (i.e. humans infected with WNV), the immune system is rapidly engaged and drives antiviral immune responses necessary for controlling virus replication, limiting virus-mediated pathology, and providing immunity to re-infection (Figure 1a). Accordingly, the innate and adaptive immune systems are essential for providing protection against WNV infection [5]. In particular, type I IFN and related antiviral defenses are triggered following recognition of WNV infection and activation of the RIG-I like receptor (RLR), Toll-like receptor (TLR), and NOD-like receptor (NLR) signaling pathways. Infection analysis of *RIG-I*^{-/-} or *MDA5*^{-/-} macrophages, dendritic cells and fibroblasts revealed that RIG-I is activated early during infection whereas MDA5 is required for enhancing and sustaining type I IFN and interferon-stimulated gene (ISG) expression [14–16]. Furthermore, *in vivo* studies have demonstrated that RLR signaling is required for protection as well as controlling peripheral organ and CNS viral burden, limiting virus-mediated pathology, and programming protective immunity to WNV infection [5,17]. Similarly, the TLRs [18,19] and NLRs [20,21] have been shown to restrict virus replication in a cell and tissue-specific manner and regulate protective CNS immunity during WNV infection. Additionally, components of the innate immune cellular responses, including natural killer cells [22,23], neutrophils [8], and $\gamma\delta$ T cells [24], and cell-mediated and humoral adaptive immune responses are critical for protection against WNV infection (as reviewed in greater detail in [5]). Studies in humans infected with WNV have been limited, however, certain risk factors for symptomatic infection outcome include advanced age, immunocompromised status [25], genetic factors [26,27,28], and reduced expansion of regulatory T cells [29].

Systems biology approach to study the host response to WNV infection

Traditional scientific methodologies to study the host response to WNV infection have been paramount for identifying the viral and host genetic factors that control virus replication and infection outcome (Figure 1b). While extremely important, this approach often involves studying individual components of the immune system (i.e. knockout mice) and results in providing a narrow and simplified representation of the host response to viral infection. Systems biology is a scientific approach that integrates multiple disciplines, including biology, immunology, virology, computer science, and mathematics, to develop a quantitative and a comprehensive understanding of a biological phenomenon (e.g. host response to virus infection). This approach consists of an iterative cycle that begins with collecting experimental data through various ‘omics’-based technologies (e.g. transcriptomics,

proteomics, lipidomics, and metabolomics). Next, these data sets are carefully integrated and analyzed using mathematics and computers to generate complex biological networks that define relationships between gene sets from different experimental conditions (wild type versus mutant virus, multiplicity of infection, time, etc.). More sophisticated computational analysis can identify regulatory nodes, hubs, or bottlenecks that would suggest a regulatory mechanism for a given biological phenomenon. The next step of this process, and probably one of the most important, is to validate these computational models through experimentation. This typically involves perturbation-based analysis using knockout mice or various techniques to silence gene expression (short-hairpin RNAs (shRNA), small interfering RNAs (siRNA), CRISPR/CAS systems, etc.). Finally, the newly generated biological model can be further refined through an additional round of hypothesis-driven research, perturbation-based experiments, and high-throughput based assays. The ultimate goal of this iterative process is to identify novel host targets of therapeutic intervention or pathways that can be modulated for enhancing immunogenicity during vaccination. Such approaches are now being harnessed to model pathogen-host interactions and immune response networks during hepatitis C virus [30–34], influenza virus [35–37,38] and severe acute respiratory syndrome-associated coronavirus infections [35,36,39,40].

These types of studies with WNV have been limited, however, our group recently used a systems biology approach to define the innate immune molecular signatures that control tissue tropism to WNV infection. Normally in wild-type mice, WNV replication is limited to the skin, draining lymph node, spleen, and central nervous system [5]. Genetic deletion of innate immune signaling components, such as MAVS [17], IRF-3 [41] or the type I IFN receptors [42], leads to productive virus replication in normally non-permissive organs, such as the liver. Thus, in this study, we compared the molecular signatures between the spleen (permissive) and liver (nonpermissive) compartments following WNV infection [22]. Transcriptional profiling revealed distinct gene expression patterns between these two organ compartments during WNV infection. Furthermore, functional genomics analysis and pathway modeling not only confirmed the importance type I IFN signaling networks for controlling tissue tropism, but revealed a previously unappreciated role for natural killer cell-mediated restriction of WNV replication within the liver. Biological validation and perturbation based studies revealed that natural killer cells indeed expand in the liver following WNV infection and both the RLR and type I IFN signaling pathways are important for mediating natural killer cell expansion and activity. Through these studies, we developed a model, whereby gene networks regulated by the RLR and type I IFN signaling axis impart restriction of virus replication and facilitate natural killer cell

Download English Version:

<https://daneshyari.com/en/article/5806782>

Download Persian Version:

<https://daneshyari.com/article/5806782>

[Daneshyari.com](https://daneshyari.com)